D. Boral Capital Reaffirms Buy Rating for Cytosorbents (NASDAQ:CTSO)

D. Boral Capital reiterated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a report published on Tuesday morning,Benzinga reports. They currently have a $10.00 price objective on the medical research company’s stock.

Separately, StockNews.com started coverage on Cytosorbents in a research report on Wednesday, March 26th. They issued a “hold” rating on the stock. Two equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Performance

Shares of NASDAQ:CTSO opened at $1.00 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The stock has a market cap of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. The business has a 50-day moving average price of $1.07 and a 200-day moving average price of $1.05.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.04. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. The company had revenue of $9.20 million during the quarter, compared to analyst estimates of $10.09 million. Equities analysts predict that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently modified their holdings of the business. Avenir Corp raised its holdings in Cytosorbents by 4.0% in the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock worth $2,815,000 after purchasing an additional 118,387 shares during the period. Skylands Capital LLC increased its position in shares of Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after buying an additional 26,195 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Northern Trust Corp lifted its position in shares of Cytosorbents by 22.3% during the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after buying an additional 16,701 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.